by healthadvances Posted on January 13, 2023 Reflections on BIOHK2022: Asia Biotech Market and the 2023 Outlook Read More
by healthadvances Posted on January 4, 2023 Maturation of Modalities and Targeting Strategies in Oncology: A Review of Recent and Upcoming Approvals Read More
by healthadvances Posted on December 21, 2022 Allogeneic Cell Therapy: ASH 2022 Takeaways and Future Outlook Read More
by healthadvances Posted on November 15, 2022 Let’s Talk About Vaginismus and Digital Health Read More
by healthadvances Posted on October 31, 2022November 1, 2022 Relyvrio Approval: Lessons Learned Read More
by healthadvances Posted on July 27, 2022July 27, 2022 What Do the Next 10 Years Hold for CRISPR? Read More
by healthadvances Posted on July 21, 2022 Digital Biomarkers – The Future of Precision Medicine Read More
by healthadvances Posted on July 14, 2022 Impact of Innovation on Market Access for Wound Care Products Read More
by healthadvances Posted on July 11, 2022July 12, 2022 Demystifying SARS-CoV-2 Testing for COVID-19 (Fourth Edition – The Long-Term Dx Industry Impact) Read More
by healthadvances Posted on July 6, 2022July 21, 2022 Xenotransplantation: Market Disrupter or Expander? Read More
by healthadvances Posted on June 24, 2022June 24, 2022 From Treating Cancer to Curing Cancer – The Promise of mRNA Vaccines in Oncology Read More
by healthadvances Posted on September 18, 2020 How COVID-19 Testing Demand Threw off Thermo Fisher’s Acquisition of Qiagen Read More
by healthadvances Posted on July 16, 2020July 11, 2022 Demystifying SARS-CoV-2 Testing for COVID-19 (Third Edition: Updates and Trends) Read More
by healthadvances Posted on April 24, 2020 The Great Lockdown of 2020: Will the Life Sciences Emerge Unscathed? Read More
by healthadvances Posted on February 27, 2019November 13, 2020 Danaher’s Massive Biopharma Acquisition: It’s the Fit that Counts Read More
